Three’s company

For those still not convinced by 10-year outcomes of Z0011 and IBCSG 23-10, last week brought us the same song different verse from AMAROS. Just like in 23-10, women with cT1-2N0 breast cancer were randomized upfront in a non-inferiority design to +/- completion axillary dissection if sentinel node dissection revealed disease. Of note, unlike Z0011, women received either breast conservation (82%) or mastectomy (18%), and 5% in each arm had ≥3 positive sentinel nodes. Also in keeping with recent themes, the authors at interim analysis “realised that the projected number of events would probably never occur.” TBL: Notwithstanding the huge confidence intervals making this a “negative” trial, 10-year rates of axillary recurrence were <1% with and <2% without completion axillary dissection and of any locoregional recurrence was roughly 4% either way. | Rutgers, SABCS 2018